Recombinant escherichia coli for producing D-mannose and preparation method thereof
By modifying gene expression and introducing specific enzyme genes in E. coli, the recombinant strain was constructed, and the problems of environmental pollution, strict reaction conditions and low conversion rates in traditional D-mannose production methods were solved, achieving efficient and environmentally friendly D -Mannose production.
Patent Information
- Application Number
- CN202411175226.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-22
AI Technical Summary
The traditional D-mannose production methods have problems such as environmental pollution, strict reaction conditions, low conversion rate and difficulty in separation. The conversion rate of biological methods is low and difficult to separate, which limits its application.
Recombinant strains were constructed by inducing or reducing pfkA, pfkB, zwf and lpxM gene expression in E. coli, and introducing D-mannose 6-phosphate isomerase, mannose phosphate mutase and GDP-mannose hydrolase genes in E. coli, and constructing recombinant strains To improve the production efficiency of D-mannose.
It has achieved efficient synthesis of high-purity D-mannose under mild conditions using D-glucose as raw material, shortened the production cycle, and provided a cheap and environmentally friendly production route, suitable for large-scale applications.
Smart Images

Figure FT_1 
Figure SMS_1 
Figure SMS_2
Abstract
Description
Technical Field
[0001] The invention belongs to the field of food chemical industry, and particularly relates to a recombinant Escherichia coli for producing D-mannose and a preparation method thereof. Background Art
[0002] D-mannose, as a simple reducing monosaccharide commonly found in nature, is not only a key component of a variety of polysaccharides and glycoproteins, but is also increasingly becoming an emerging dietary supplement. Its application range includes food, health products, skin care products, pharmaceutical industry, poultry and animal husbandry, etc. D-mannose is a natural sweetener and functional ingredient in the food and beverage industry, and the demand continues to rise. Consumers' preference for natural and healthy foods has driven the market's pursuit of D-mannose. Compared with sucrose and D-glucose, its sweetness reaches 60% and 86% respectively, and its low calorie and non-toxic properties make D-mannose widely used in the food, medicine, cosmetics and food additive industries. D-mannose can be used in beverages, cakes, candies, dairy products and other foods to enhance sweetness, optimize taste and provide functional characteristics. At present, domestic research on the functions of D-mannose mainly focuses on regulating the immune system, promoting wound healing, anti-inflammatory, inhibiting tumor growth, avoiding bacterial infections, etc., especially in the field of urinary tract infections.
[0003] There are three main methods for traditional production of D-mannose: extraction, chemical synthesis and biological methods. The extraction method uses a variety of raw materials such as palm kernels, coffee grounds, acai berry seeds and red date powder to extract D-mannose, involving hydrolysis, filtration, separation and purification. Although this method stands out for its advantages of easy availability of raw materials and high yield, it faces environmental pollution problems due to the use of high temperature and strong acid and alkali, and is also restricted by region and season. The chemical synthesis method produces D-mannose through the isomerization reaction of D-glucose catalyzed by molybdate, which needs to be carried out at a temperature of 100 to 150°C and a pH of about 3.0. Its challenges lie in harsh reaction conditions, low conversion rate and high difficulty in separation and purification, although the source of raw materials is stable. At the same time, the biological method converts D-fructose or D-glucose into D-mannose through enzymatic reactions, showing the advantages of stable raw material sources, mild reaction conditions and low cost. Although the mild conditions and low cost of the biological method have won it an advantage, its low conversion rate (20%~30%) and difficulty in separation limit its further application. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a recombinant bacterium which utilizes raw materials such as D-glucose and glycerol to supply microbial growth and prepares D-mannose as the raw material.
[0005] In order to solve the above technical problems, the first aspect of the present invention provides a recombinant bacterium, which is a recombinant bacterium obtained by carrying out the following transformations A) and B) in Escherichia coli; A) inhibiting or reducing the expression of the pfkA gene, the pfkB gene, the zwf gene and / or the lpxM gene in the Escherichia coli; B) increasing the expression of a gene encoding D-mannose 6-phosphate isomerase, a gene encoding phosphomannose mutase, a gene encoding phosphomannose guanylyltransferase and a gene encoding GDP-mannose hydrolase in the Escherichia coli.
[0006] In the recombinant bacteria described above, The transformation A is any of the following: A-1) inhibiting or reducing the expression of the pfkA gene, the pfkB gene, the zwf gene and the lpxM gene in the Escherichia coli; A-2) inhibiting or reducing the expression of the pfkA gene, the pfkB gene and the zwf gene in the Escherichia coli; A-3) inhibiting or reducing the expression of the pfkA gene and the pfkB gene in the Escherichia coli; A-4) inhibiting or reducing the expression of the pfkA gene in the Escherichia coli.
[0007] In the above-mentioned recombinant bacteria, the Escherichia coli is Escherichia coli MG1655.
[0008] Among the recombinant bacteria mentioned above, the preservation number of the recombinant bacteria is CGMCC No.30520.
[0009] In a second aspect, the present invention provides a method for preparing the recombinant bacteria described in the first aspect, comprising the following steps: performing the transformation according to the first aspect.
[0010] In the above method, the modification A-1) is to knock out or replace the pfkA gene, pfkB gene, zwf gene and lpxM gene; Or, the modification A-2) is to knock out or replace the pfkA gene, pfkB gene and zwf gene; Or, the modification A-3) is to knock out or replace the pfkA gene and the pfkB gene; Or, the modification A-4) is to knock out or replace the pfkA gene; Alternatively, the transformation B) is to introduce the D-mannose 6-phosphate isomerase encoding gene, the phosphomannose mutase encoding gene, the phosphomannose guanylyltransferase encoding gene and the GDP-mannose hydrolase encoding gene into the Escherichia coli.
[0011] In an embodiment of the present invention, the method described above is any one of the following: The transformation A-1) + B specifically includes replacing the pfkA gene, pfkB gene and zwf gene on the genome of E. coli MG1655 with the fragment of FRT site-Ptrc promoter-MCG sequence-TrrnB terminator shown in SEQ ID NO: 1414-6382, and replacing the lpxM gene with the FRT site shown in SEQ ID NO: 1414-1447. The obtained recombinant bacterium is MS03.
[0012] The transformation A-2) + B specifically replaces the pfkA gene, pfkB gene and zwf gene on the genome of E. coli MG1655 with the fragment of FRT site-Ptrc promoter-MCG sequence-TrrnB terminator shown in 1414-6382 of sequence 1. The obtained recombinant bacterium is MS02.
[0013] The transformation A-3)+B specifically replaces the pfkA gene and the pfkB gene on the genome of E. coli MG1655 with the fragment of FRT site-Ptrc promoter-MCG sequence-TrrnB terminator shown in 1414-6382 of sequence 1. The obtained recombinant bacterium is MS01.
[0014] The transformation A-4)+B specifically replaces the pfkA gene on the E. coli MG1655 genome with the fragment of FRT site-Ptrc promoter-MCG sequence-TrrnB terminator shown in 1414-6382 of sequence 1. The obtained recombinant bacterium is MS00.
[0015] In a third aspect, the present invention provides a recombinant bacterium prepared by the method described in the second aspect.
[0016] The recombinant bacteria mentioned above may be the bacteria with a preservation number of CGMCC No.30520.
[0017] In a fourth aspect, the present invention provides the use of the recombinant bacteria described in the first or third aspect in the preparation of a whole-cell catalyst.
[0018] In a fifth aspect, the present invention provides a whole-cell catalyst, which is prepared according to a method comprising the following steps: culturing the recombinant bacteria described in the first or third aspect in a growth medium, then inducing the culture, collecting the bacteria, and obtaining the whole-cell catalyst; The growth medium is a medium containing any one, two, three or four of glycerol, acetic acid, fatty acid, triglyceride and D-glucose.
[0019] In the above, the growth medium is specifically a glycerol growth medium.
[0020] In the above, the induction culture is to add an inducer to the growth medium and then continue the culture.
[0021] The above inducer is specifically IPTG.
[0022] The whole cell catalyst is prepared according to the method comprising the following steps: inoculating the recombinant bacteria described in the first or third aspect into 200 ml of glycerol growth medium at a 1% inoculation rate, and culturing at 37°C until the OD 600nm After the concentration of IPTG was 0.8, a final concentration of 0.5 mM IPTG was added, and the culture was continued at 37°C for 12 h. The bacteria were collected by centrifugation at 8000 g for 10 min to obtain the whole-cell catalyst.
[0023] In a sixth aspect, the present invention provides the use of the recombinant bacteria described in the first or third aspect or the whole cell catalyst described in the fifth aspect in any of the following: C1, production of D-mannose; C2, catalyzes the conversion of D-glucose into D-mannose; C3. Preparation of products for producing D-mannose; C4. Prepare products that catalyze the conversion of D-glucose into D-mannose.
[0024] The above-mentioned products are compositions or bacterial agents or other biological products.
[0025] The active ingredient of the above composition may be the recombinant bacteria and / or the metabolites of the recombinant bacteria and / or the culture of the recombinant bacteria.
[0026] The above-mentioned culture may be a substance obtained by culturing the recombinant bacteria in a microbial culture medium (i.e., a fermentation product, such as a fermentation broth containing the recombinant bacteria and a substance secreted into a liquid culture medium, or a solid fermentation product containing the recombinant bacteria and a substance secreted into a solid culture medium).
[0027] In the above, the metabolite may be a product obtained by removing the recombinant bacteria from the culture, such as culturing the recombinant bacteria in a liquid fermentation medium, collecting the fermentation broth (containing the recombinant bacteria and substances secreted into the liquid culture medium), removing the recombinant bacteria from the fermentation broth, and collecting the remaining components of the fermentation broth to obtain the metabolite of the recombinant bacteria.
[0028] The active ingredients of the above composition may also contain other biological ingredients or non-biological ingredients. Those skilled in the art may determine the other active ingredients of the above composition according to the effects of the composition.
[0029] The above composition may be the culture. The above composition may also be a bacterial agent.
[0030] The above-mentioned bacterial agent refers to a live bacterial preparation made by expanding the target microorganisms and using a carrier as an adsorbent to adsorb the fermentation liquid or solid fermentation product of the bacteria.
[0031] The above-mentioned bacterial agents may be in various dosage forms, including but not limited to liquid, emulsion, suspension, powder, granule, wettable powder or water dispersible granule, etc.
[0032] The bacterial agent may further include a carrier as required, and the carrier may be a solid carrier or a liquid carrier.
[0033] In a seventh aspect, the present invention provides a method for producing D-mannose, comprising the following steps: using D-glucose as a substrate, and performing a catalytic reaction using the recombinant bacteria described in the first or third aspect or the whole-cell catalyst described in the fifth aspect to obtain D-mannose.
[0034] In the method, before using the recombinant bacteria described in the first or third aspect to carry out a catalytic reaction, the following step is also included: the recombinant bacteria described in the first or third aspect are cultured in a growth medium and then induced, and the growth medium is a medium containing any one, two, three or four of glycerol, acetic acid, fatty acids, triglycerides and D-glucose.
[0035] In some embodiments of the present application, the growth medium may be as follows: 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 3% (g / 100mL) glycerol, 0.5% (g / 100mL) molasses, 0.5% (g / 100mL) glutaric acid, trace elements: 50μM FeCl3, 20μM CaCl2, 10μM MnCl2, 10μM ZnSO4, 2μM each of CoCl2, NiCl2, Na2MO4, Na2SeO3 and H3BO3, and the rest is water.
[0036] The inducer used in the above induction is IPTG.
[0037] The beneficial technical effects achieved by the present invention are as follows: Based on the above-mentioned large-scale production problem of D-mannose, the present invention develops a new D-mannose production route based on microbial fermentation. The method uses cheaper D-glucose and the like as production raw materials and synthesizes high-purity D-mannose in one step by microbial fermentation. The production process of D-mannose using the present invention greatly shortens the production cycle, laying a solid foundation for its wide application and development.
[0038] The recombinant strain provided by the present invention can realize the growth of microorganisms with a mixed carbon source containing components such as glycerol, and can also use a combination of carbon sources containing specific components of the above carbon sources for growth. After the microorganisms grow to a certain biomass, D-glucose is used as a raw material to synthesize D-mannose, and then a corresponding technical route for synthesizing D-mannose is established.
[0039] Collection Instructions Bacteria species: Escherichia coli Latin name: Escherichia coli Strain ID: MS03 Depository: China National Microbiological Culture Collection Administration General Microbiology Center Abbreviation of depository institution: CGMCC Address: No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing Deposit date: May 7, 2024 CGMCC Registration Number: CGMCC No.30520 Escherichia coli Escherichia coli BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 This is the HPLC test result. DETAILED DESCRIPTION
[0040] The present invention is further described in detail below in conjunction with specific embodiments, and the examples provided are only for illustrating the present invention, rather than for limiting the scope of the present invention. The examples provided below can be used as a guide for further improvements by those of ordinary skill in the art, and do not constitute a limitation of the present invention in any way.
[0041] The experimental methods in the following examples, unless otherwise specified, are all conventional methods, and are performed according to the techniques or conditions described in the literature in the field or according to the product instructions. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial channels.
[0042] Unless otherwise specified, the quantitative tests in the following examples were performed three times and the results were averaged.
[0043] Escherichia coli MG1655 (CGSC#: 6300), plasmids pKD46 (CGSC#: 7739), pKD4 (CGSC#: 7682), and pCP20 (CGSC#: 7629) were purchased from the Escherichia coli Genetic Collection of Yale University, USA.
[0044] Escherichia coli JW1176 was donated by Yong Tao's group at the Institute of Microbiology, Chinese Academy of Sciences, from the KEIO collection, and is disclosed in the document "Xiaoyu Piao, Lei Wang, Baixue Lin, Hao Chen, Weifeng Liu, Yong Tao. Metabolic engineering of Escherichia coli for production of L-aspartate and its derivative β-alanine with high stoichiometric yield. Metabolic Engineering. 2019 54: 244-254." The public can obtain the above-mentioned biological materials from the applicant, and the obtained above-mentioned biological materials are only used for repeating the experiments of the present invention and cannot be used for other purposes.
[0045] The primer sequences in the following examples are as follows: Table 1 shows the primer sequences
[0046] In the present invention, the NCBI Reference Sequence Number (NCBI Reference Sequence) of 6-phosphofructokinase 1 (pfkA) is NP_418351.1 (09-MAR-2022), and the NCBI Reference Sequence Number (NCBI Reference Sequence) of its encoding gene is Gene ID: 948412 (02-May-2024).
[0047] In the present invention, the NCBI Reference Sequence Number (NCBI Reference Sequence) of 6-phosphofructokinase 2 (pfkB) is NP_416237.3 (09-MAR-2022), and the NCBI Reference Sequence Number (NCBI Reference Sequence) of its encoding gene is Gene ID: 946230 (02-May-2024).
[0048] In the present invention, the NCBI Reference Sequence Number (NCBI Reference Sequence) of 6-phosphate glucose dehydrogenase (zwf) is NP_416366.1 (09-MAR-2022), and the NCBI Reference Sequence Number (NCBI Reference Sequence) of its encoding gene is Gene ID: 946370 (02-May-2024).
[0049] In the present invention, the NCBI Reference Sequence Number (NCBI Reference Sequence) of lipid A biosynthesis myristoyltransferase (lpxM) is NP_416369.1 (09-MAR-2022), and the NCBI Reference Sequence Number (NCBI Reference Sequence) of its encoding gene is Gene ID: 945143 (02-May-2024).
[0050] Unless otherwise specified, all replacements in the embodiments are replacements.
[0051] Example 1. Construction of recombinant Escherichia coli MS03 In this example, a basic bacterium MS03 was prepared that can use glycerol as a carbon source for bacterial growth and convert D-glucose into D-mannose. The preparation method of the strain is as follows, and the primers used in the preparation process are shown in Table 1.
[0052] 1. Construction of strain MS00 1) Preparation of ManA-CpsG-CpsB-Gmm gene fragment The genes of D-mannose 6-phosphate isomerase (ManA), phosphomannose mutase (CpsG), phosphomannose guanylyltransferase (CpsB) and GDP-mannose hydrolase (Gmm) were artificially synthesized, and RBS were designed between adjacent genes. The fragment MCG was designed to contain the sequences of ManA, RBS, CpsG, RBS, CpsB, RBS and Gmm in sequence. The nucleotide sequence of the entire MCG sequence was sequence 1, positions 1522-6042. The entire sequence was synthesized by Suzhou Jinweizhi Biotechnology Co., Ltd.
[0053] In sequence 1, positions 1522-2697 are ManA, positions 2705-2709 are RBS, positions 2717-4087 are CpsG, positions 4095-4099 are RBS, positions 4107-5543 are CpsB, positions 5551-5555 are RBS, and positions 5563-6042 are Gmm.
[0054] The fragment MCG shown in position 1522-6042 of sequence 1 was used as a template and primers CMG-1 / CMG-2 were used for PCR amplification to obtain the amplified product MCG. Primers Trc-1 / Trc-2 were used to amplify the commercial plasmid pTrc-99A (Shanghai Zeye Biotechnology Co., Ltd., catalog number ZY-64292) as a template to obtain the vector fragment pTrc. The MCG fragment was constructed on pTrc using the Gibson assembly method and verified by sequencing to obtain the pTrc-MCG plasmid.
[0055] 2) Preparation of pfkA site-integrated targeting fragment Primers KD-BB-R and pfkA-F were used to perform PCR amplification with plasmid pKD4 as a template, and a target band of about 1500 bp was recovered to obtain fragment A1, which contained a kanamycin resistance gene fragment with FRT sites at both ends (positions 1-1447 in sequence 1, of which FRT-1 was positions 21-54, Kan resistance gene was positions 429-1223, and FRT-2 was positions 1414-1447).
[0056] Primers KD-BB-F and pfkA-R were used to perform PCR amplification with the pTrc-MCG plasmid as a template, and a target band of about 5000 bp was recovered to obtain fragment A2. The MCG gene cluster in fragment A2 was regulated by the trc promoter and rrnB terminator (positions 1448-6382 in sequence 1, where the Trc promoter is positions 1448-1521 and the rrnB terminator is positions 6296-6382).
[0057] Primers pfkA-F and pfkA-R were used, and A1 and A2 mixture were used as modules for overlap PCR amplification, and the target band of about 4700 bp was recovered to obtain the target fragment KA. Fragment KA contains the upstream homology arm of the pfkA gene-the kanamycin resistance gene with FRT sites on both sides-the Ptrc promoter-the MCG sequence-the TrrnB terminator-the downstream homology arm of the pfkA gene.
[0058] 3) The MCG fragment was integrated into the pfkA site of MG1655 E. coli MG1655 was prepared by the CaCl2-MgCl2 method. The pKD46 plasmid was transformed into MG1655 and cultured overnight at 30 °C on an LB plate containing 50 μg / mL ampicillin. A single clone was picked and inoculated into 100 mL of liquid LB medium containing 50 μg / mL ampicillin at a 1% inoculation rate. The culture was shaken at 30 °C and 220 rpm, and the bacterial OD was measured at regular intervals. 600 When the OD600 value was about 0.2, L-arabinose was added to the culture medium to a final concentration of 10 mM to induce full expression of the λ-red recombinase protein on pKD46, and the culture was continued until the OD 600 When the p-value is 0.4-0.6, stop culturing; prepare MG1655 electrotransformation competent cells. Then transform the targeting fragment KA prepared in 2 above into MG1655 electrotransformation competent cells, spread on LB medium plates containing 50 μg / mL kanamycin, and culture at 37 °C overnight until monoclonal colonies grow.
[0059] 4) Screening and identification of positive transformants Randomly pick a single colony after overnight culture in step 3) above, culture at 37 °C, and screen the positive recombinant bacteria by PCR. Use Osaibo 2×Taq Mix for initial screening of bacterial solution PCR: use bacterial solution as template, use the knockout site external sequence primer pfkA-U (Table 1) and the kanamycin resistance fragment internal sequence primer PK used for knockout screening marker for amplification, and the 1200bp target band amplified is the positive transformant for further resistance elimination operation.
[0060] Prepare competent cells from positive clones; transfer pCP20 plasmid into competent cells, spread on LB medium plates containing 50μg / mL ampicillin, and culture at 30°C overnight; pick a single clone in LB liquid medium containing 50μg / mL ampicillin, culture at 37°C for 5h, streak on an LB medium plate without antibiotics, and culture at 37°C overnight. Pick a single clone and transfer it to LB medium without antibiotics and culture at 37°C for 5h. If the culture cannot grow after being transferred to LB medium containing 50μg / mL kanamycin, further PCR identification is performed: PCR amplification of the bacterial liquid is performed using primers (pfkA-U / pfkA-A), and the positive single clone is amplified with a target band of about 5000bp.
[0061] The positive clone with the resistance fragment eliminated was named recombinant bacterium MS00, which was obtained by replacing the pfkA gene on the genome of Escherichia coli MG1655 with the fragment of FRT site-Ptrc promoter-MCG sequence-TrrnB terminator shown in sequence 1, 1414-6382, while other genes remained unchanged.
[0062] 2. Construction of strain MS01 The recombinant bacterium MS01 is obtained by replacing the pfkA gene and the pfkB gene on the genome of Escherichia coli MG1655 with the fragment of FRT site-Ptrc promoter-MCG sequence-TrrnB terminator shown in sequence 1, 1414-6382, while other genes remain unchanged.
[0063] The preparation method of recombinant bacteria MS01 is basically the same as the preparation method of recombinant bacteria MS00 in 1 above, except that MG1655 electroporation competent cells are replaced with MS00 electroporation competent cells. The targeting fragment KA was replaced by KB. The construction method of the targeting fragment KB was as follows: primers KD-BB-R and pfkB-F were used, plasmid pKD4 was used as a template for PCR amplification, and a target band of about 1500 bp was recovered to obtain fragment B1.
[0064] Primers KD-BB-F and pfkB-R were used to perform PCR amplification with pTrc-MCG plasmid as a template, and a target band of about 5000 bp was recovered to obtain fragment B2.
[0065] Primers pfkB-F and pfkB-R were used, and the mixture of B1 and B2 was used as a module for overlap PCR amplification to obtain a target band of about 4700 bp and obtain the target fragment KB. The KB fragment contains the upstream homology arm of the pfkB gene-the kanamycin resistance gene with FRT sites on both sides-the Ptrc promoter-the MCG sequence-the TrrnB terminator-the downstream homology arm of the pfkB gene.
[0066] The screening primers for positive transformants were pfkB-U (Table 1) and primer PK, and the 1200 bp was obtained as a positive transformant. The identification primers for the positive single clone that eliminated resistance were (pfkB-U / pfkB-A), and the 5000 bp was obtained as a positive single clone, namely MS01.
[0067] 3. Construction of strain MS02 The recombinant bacterium MS02 is obtained by replacing the pfkA gene, pfkB gene and zwf gene on the genome of Escherichia coli MG1655 with the fragment of FRT site-Ptrc promoter-MCG sequence-TrrnB terminator shown in sequence 1, 1414-6382, while other genes remain unchanged.
[0068] The preparation method of recombinant bacteria MS02 is basically the same as the preparation method of recombinant bacteria MS00 in 1 above, except that MG1655 electroporation competent cells are replaced with MS01 electroporation competent cells. The targeting fragment KA was replaced by KZ. The method for constructing the targeting fragment KZ was as follows: primers KD-BB-R and zwf-F were used, plasmid pKD4 was used as a template for PCR amplification, and a target band of about 1500 bp was recovered to obtain fragment Z1.
[0069] Primers KD-BB-F and zwf-R were used to perform PCR amplification with pTrc-MCG plasmid as a template, and a target band of about 5000 bp was recovered to obtain fragment Z2.
[0070] Primers zwf-F and zwf-R were used, and a mixture of Z1 and Z2 was used as a module for overlap PCR amplification to obtain a target band of about 4700 bp and obtain the target fragment KZ. The KZ fragment contains the upstream homology arm of the zwf gene-the kanamycin resistance gene with FRT sites on both sides-the Ptrc promoter-the MCG sequence-the TrrnB terminator-the downstream homology arm of the zwf gene.
[0071] The screening primers for positive transformants were zwf-U (Table 1) and primer PK, and the positive transformants were 1200 bp. The identification primers for the positive clones that eliminated resistance were (zwf-U / zwf-A), and the positive clones were 5000 bp, which was MS02.
[0072] 4. Construction of strain MS03 The recombinant bacterium MS03 is obtained by replacing the pfkA gene, pfkB gene and zwf gene on the genome of Escherichia coli MG1655 with the fragment of the FRT site-Ptrc promoter-MCG sequence-TrrnB terminator shown in sequence 1, 1414-6382, and replacing the lpxM gene with the FRT site shown in sequence 1, 1414-1447, while other genes remain unchanged.
[0073] The preparation method of recombinant bacteria MS03 is basically the same as the preparation method of recombinant bacteria MS00 in 1 above, except that MG1655 electroporation competent cells are replaced with MS02 electroporation competent cells. The target fragment KA was replaced with KL, and the target fragment KL was PCR amplified using primers lpxM-F and lpxM-R with plasmid pKD4 as a template to obtain a target band of about 1500 bp and obtain fragment KL. lpxM gene upstream homology arm - kanamycin resistance gene with FRT sites on both sides - lpxM gene downstream homology arm.
[0074] The screening primers for positive transformants were lpxM-U (Table 1) and primer PK, and the obtained 1200bp was a positive transformant. The identification primers for the positive single clone that eliminated resistance were (lpxM-U / lpxM-A), and the obtained 200bp was a positive single clone, namely MS03.
[0075] The recombinant bacterium MS03 was deposited in the General Microbiology Center of China Microorganism Culture Collection Administration (CGMCC) on May 7, 2024, at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing; the deposit number is CGMCC No.30520, and the classification name is Escherichia coli Escherichia coli .
[0076] Example 2: Application of recombinant Escherichia coli MS03 in the preparation of D-mannose using D-glucose as substrate 1. Glycerol Growth Medium Composition Growth medium components and final concentrations are as follows: 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM NH4Cl, 5 mM Na2SO4, 2 mM MgSO4, 3% (g / 100mL) glycerol, 0.5% (g / 100mL) molasses, 0.5% (g / 100mL) glutaric acid, trace elements: 50μM FeCl3, 20μM CaCl2, 10μM MnCl2, 10μM ZnSO4, 2μM each of CoCl2, NiCl2, Na2MO4, Na2SeO3 and H3BO3, and the rest is water.
[0077] 2. Transformation medium composition 25 mM Na2HPO4, 25 mM KH2PO4, 50 mM MgCl2, 12% (g / 100mL) D-glucose, the balance is water.
[0078] 3. Bacterial culture and enzyme induction The wild-type strain MG1655, recombinant strain MS03, and control strains MG1655, MS00, MS01, and MS02 were inoculated at 1% in a shake flask containing 200 ml of glycerol growth medium and cultured at 37°C until OD 600nm After the concentration of IPTG was 0.8, a final concentration of 0.5 mM IPTG was added, and the culture was continued at 37°C for 12 h. The bacteria were collected by centrifugation at 8000 g for 10 min to obtain the whole-cell catalyst.
[0079] 4. Whole-cell catalysis of D-mannose Resuspend 150 mg of the collected bacteria obtained in step 3 above in a shake flask containing 10 ml of transformation medium and react at 220 r / min and 37 °C. The reaction process was regularly detected using pH test paper, and 0.1 M NaOH and HCl solutions were used to adjust the pH to 7.0. After 24 hours of reaction, the reaction product was centrifuged at 8000 g for 10 minutes, and the supernatant was filtered through a 0.22 μm filter membrane, and the D-mannose content in the supernatant was detected by HPLC. HPLC used a Hi-Plex Ca column (300 mm × 7.7 mm, 8 μm); the mobile phase was ultrapure water, the flow rate was 0.5 mL / min; the column temperature was 78 °C; the detector was a differential refractive index detector; the temperature was 40 °C.
[0080] D-mannose standard was purchased from Shanghai Yuanye Biotechnology (Cat. No. S48276). The HLPC standard curve was prepared using the D-mannose standard, and the equation for D-mannose concentration was obtained ( Figure 1 A is the standard track, Figure 1 B is the HPLC result of the standard product).
[0081] The conversion rate is the ratio of D-mannose production to D-glucose consumption in the whole-cell catalytic stage (step 4)*100%.
[0082] The results are shown in Table 2. The D-mannose production of the wild-type strain MG1655 is 0, while the production and conversion rate of the modified engineered strains MS00, MS01, and MS02 gradually increase. The D-mannose production of the engineered strain MS03 can reach 97.70±3.56 g / L, and the conversion rate can reach 81.42±2.97%. This shows that this scheme can achieve a high efficiency of using D-glucose raw materials to catalyze the synthesis of D-mannose by whole-cell catalysis.
[0083] Table 2 shows the D-mannose production and conversion rate of each strain
[0084] In addition, the purity of D-mannose in the supernatant of engineered strain MS03 was high, and no other sugars were significantly detected under the same HPLC conditions ( Figure 1 C), which is beneficial to simplify the downstream separation and purification process.
[0085] 5. Comparison of the effects of different growth media on the culture of engineered strain MS03 and D-mannose whole-cell catalysis According to steps 1-4 in the above Example 2, the engineered strain MS03 was used for whole-cell catalysis of D-mannose, except that in step 3, in addition to using the glycerol growth medium, the glycerol growth medium was replaced by growth medium 0 and growth medium 1. The yield and conversion rate of D-mannose catalyzed by the whole-cell after using the above three growth media were compared.
[0086] The composition of growth medium 0 is as follows: based on the glycerol growth medium, glycerol is not contained, and other components remain unchanged. The composition of growth medium 1 is as follows: based on the glycerol growth medium, glycerol is not contained, and 2% (g / 100mL) acetic acid, 1% (g / 100mL) triglyceride, 0.01% (g / 100mL) lipase and 0.5% D-glucose are contained, and other components remain unchanged.
[0087] The results showed that when using growth medium 0, the strain could not grow and the D-mannose production was 0. When using growth medium 1, the D-mannose production could reach 84.53±5.20 g / L and the conversion rate could reach 70.44±4.33%.
[0088] The present invention has been described in detail above. It will be apparent to those skilled in the art that the present invention may be implemented in a wide range under equivalent parameters, concentrations and conditions without departing from the spirit and scope of the present invention and without the need for unnecessary experimentation. Although the present invention provides specific embodiments, it should be understood that further improvements may be made to the present invention. In short, according to the principles of the present invention, this application intends to include any changes, uses or improvements to the present invention, including changes made by conventional techniques known in the art that depart from the scope disclosed in this application. Applications of some of the basic features may be made within the scope of the following appended claims.
Claims
1. A recombinant bacterium, which is a recombinant bacterium obtained by carrying out the following transformations A) and B) in Escherichia coli; A) inhibiting or reducing the expression of the pfkA gene, the pfkB gene, the zwf gene and / or the lpxM gene in the Escherichia coli; B) increasing the expression of a gene encoding D-mannose 6-phosphate isomerase, a gene encoding phosphomannose mutase, a gene encoding phosphomannose guanylyltransferase and a gene encoding GDP-mannose hydrolase in the Escherichia coli.
2. The recombinant bacterium according to claim 1, characterized in that: The transformation A is any of the following: A-1) inhibiting or reducing the expression of the pfkA gene, the pfkB gene, the zwf gene and the lpxM gene in the Escherichia coli; A-2) inhibiting or reducing the expression of the pfkA gene, the pfkB gene and the zwf gene in the Escherichia coli; A-3) inhibiting or reducing the expression of the pfkA gene and the pfkB gene in the Escherichia coli; A-4) inhibiting or reducing the expression of the pfkA gene in the Escherichia coli.
3. The recombinant bacterium according to claim 1 or 2, characterized in that: The Escherichia coli is Escherichia coli MG1655.
4. The recombinant bacterium according to any one of claims 1 to 3, characterized in that: The deposit number of the recombinant bacteria is CGMCC No. 30520.
5. A method for preparing the recombinant bacterium according to any one of claims 1 to 4, comprising the following steps: performing the transformation according to any one of claims 1 to 3.
6. The recombinant bacteria prepared by the method according to claim 5.
7. Use of the recombinant bacterium according to any one of claims 1 to 4 or the recombinant bacterium according to claim 6 in the preparation of a whole-cell catalyst.
8. A whole-cell catalyst, prepared by a method comprising the following steps: culturing the recombinant bacteria according to any one of claims 1 to 6 or the recombinant bacteria according to claim 7 in a growth medium, then inducing the culture, collecting the bacteria, and obtaining the whole-cell catalyst; The growth medium is a medium containing any one, two, three or four of glycerol, acetic acid, fatty acid, triglyceride and D-glucose.
9. Use of the recombinant bacteria according to any one of claims 1 to 3, the recombinant bacteria according to claim 6, or the whole-cell catalyst according to claim 8 in any of the following: C1, production of D-mannose; C2, catalyzes the conversion of D-glucose into D-mannose; C3. Preparation of products for producing D-mannose; C4. Prepare products that catalyze the conversion of D-glucose into D-mannose.
10. A method for producing D-mannose, comprising the following steps: using D-glucose as a substrate, and carrying out a catalytic reaction using the recombinant bacteria according to any one of claims 1 to 4 or the recombinant bacteria according to claim 6 or the whole-cell catalyst according to claim 8 to obtain D-mannose.
Citation Information
Cited By
Recombinant bacillus subtilis for producing L-fucose as well as construction method and application of recombinant bacillus subtilis
CN116355822A
A recombinant bacillus subtilis for producing L-fucose and a construction method and application thereof
CN116355822B
L-histidine production strain as well as construction method and application thereof
CN120608078A
L-histidine production strain and construction method and application thereof
CN120608078B
Microbial production of d-sedoheptulose
WO2026187514A1
